Research & Development

The rapid progression and accumulation of knowledge of cancer biology has accelerated identification of genes involved in diseases. Such information has been applied for the development of novel drugs, and led to the success of molecular-targeted drugs in cancer.


In the field of anti-cancer drugs, molecular-targeted therapies such as antibodies and small molecule compounds have been developed and their efficacy has been impressively proven in clinical practice. However, the number of molecular targeted drugs is still limited, and the development of novel drugs with high efficacy and a minimum risk of adverse events is expected in many kinds of cancers.


We at OncoTherapy Science, Inc. have been giving our best efforts to perform the research and development of novel molecular-targeted anti-cancer drugs using OTS’s fundamental technologies to deliver the light of hope to many patients suffering from cancers and relieve their anguish.

R&D for highly efficacious anti-cancer drug

Pursuing “To develop anti-cancer medicine and anti-cancer therapy with high efficacy and minimum risk of adverse events, and to win the war against cancer”, OTS has been conducting research and development, by collaborating with Professor Yusuke Nakamura, a genomics pioneer.

Platform Technologies of OTS

We applied laser microbeam microdissection (LMM) that obtains a highly pure population of cancer cells from cancer tissues and genome-wide cDNA microarray. Together with these technologies that provide comprehensive gene expression profile analyses and gene function analyses as fundamental technologies, we have identified suitable target genes.

Drug Discovery Research

OTS have already identified a number of cancer-specific-genes that would be applicable for development of molecular-targeted anti-cancer therapies. OTS has been pursuing the medicinal discovery research with understanding the subcellular localization, mode of function, and immunogenicity of the target cancer-specific-genes.

Pipeline

More details are available here: Pipeline of OTS groups and our business partners (at clinical stage)
back to top